Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV

Blood

Volumn 112, Issue 4, 2008, Pages 1205-1213

  Minard Colin, Veronique ^a   Xiu, Yan ^a   Poe, Jonathan C ^a   Horikawa, Mayuka ^a   Magro, Cynthia M ^b   Hamaguchi, Yasuhito ^a   Haas, Karen M ^a   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD20 ANTIBODY; CLODRONIC ACID; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; FC GAMMA RECEPTOR IV; FC RECEPTOR; IMMUNOGLOBULIN RECEPTOR; UNCLASSIFIED DRUG; CD20 ANTIGEN; FCGR1 PROTEIN, MOUSE; FCGR3 PROTEIN, MOUSE; FCGR4 PROTEIN, MOUSE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DRUG MECHANISM; GENETIC MANIPULATION; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR CELL; TUMOR VOLUME; ANIMAL; DISEASE MODEL; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; METHODOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; DISEASE MODELS, ANIMAL; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; LYMPHOMA, B-CELL; MACROPHAGES; MICE; RECEPTORS, IGG; TREATMENT OUTCOME;

EID: 51649123832     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-135160     Document Type: Article

References (50)

1. Anderson KG, Bates MP, Slaughenhoupt B, Pinkus G. Schlossman SF. Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63:1424-1433.
2. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol To-day. 1994;15:450-454.
3. Maloney DG, Grille- LA, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-3274.
4. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26:3603-3613.
5. Reft ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
6. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644-1652.
7. ++ conductance found constitutively in B lymphocytes. J Cell Biol. 1993;121:1121-1132.
8. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rit-uximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood. 2002;99:1314-1319.
9. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to ritux-imab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001 ;98:3383-3389.
10. Cragg MS, M. MS, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101:1045-1052.
11. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of Rituximab in vivo. J Immunol. 2003;171:1581-1587.
12. Bellosillo B, Villamor N, Lopez-GuillermoA, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 2001 ;98:2771-2777.
13. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MHJ. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Hematol. 2001 ;115:807-811.
14. + cells by rituximab. Blood. 2003;101:1071 -1079.
15. Treon SP, Mitsiades C. Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother. 2001 ;24:263-271.
16. Weng W-K, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood. 2001;98:1352-1357.
17. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Transac. 1997;25:705-708.
18. Clynes RA, Towers TL, PrestaLG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443-446.
19. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199:1659-1669.
20. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of FC7 receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med. 2006;203:743-753.
21. Tedder TF, Baras A, Xiu Y. FC7 receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol. 2006;28:351-364.
22. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817-826.
23. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738-2743.
24. Golay J, Cittera E, Di Gaetano N, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica. 2006;91:176-183.
25. Cittera E, Leidi M, Buracchi C, et al. The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. J Immunol. 2007;178:6616-6623.
26. Uchida J, Lee Y, Hasegawa M, et al. Mouse CD20 expression and function. Int Immunol. 2004;16:119-129.
27. Adams JM, Harris AW, Pinkert CA, et al. Thec-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318:533-538.
28. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The Eμ-myc transgenic mouse: a model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988;167:353-371.
29. Bruhns P, Samuelsson A, Pollard JW, Ravetch J. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity. 2003:18:573-581.
30. van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174:83-93.
31. 2MDP-liposome-mediated macrophage depletion. Blood. 1995;86:183-192.
32. Duncan AR, Winter G. The binding site for C1q on IgG. Nature. 1988;332:738-740.
33. Haas KM, Sen S, Sanford IG, Miller AS, Poe JC, Tedder TF. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol. 2006;177:3063-3073.
34. Sato S. Ono N, Steeber DA, Pisetsky DS, Tedder TF. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J Immunol. 1996;157:4371-4378.
35. Gazzano-Santoro H, Ralph P, Ryskamp TC, Chen AB, Mukku VR. A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J Immunol Methods. 1997;202:163-171.
36. Tu AH, Fulgham RL, McCrory MA, Briles DE, Szalai AJ. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun. 1999;67:4720-4724.
37. Hamaguchi Y, Uchida J, Cain DW, et al. The peritoneal cavity provides a protective niche tor B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol. 2005;7:4389-4399.
38. Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med. 1999;189:179-185.
39. Osmers I, Szalai AJ, Tenner AJ, Barnum SR. Complement in BuB/BnJ mice revisited: serum C3 levels and complement opsonic activity are not elevated. Mol Immunol. 2006;43:1722-1725.
40. van den Berg CW, Aerts PC, van Dijk H. In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje. J Immunol Methods. 1991 ;136:287-294.
41. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. FC7RIV: A novel FcR with distinct IgG subclass specificity. Immunity. 2005;23:41-51.
42. b immune complexes activate macrophages through FC7RIV binding. Nat Immunol. 2007;8:762-771.
43. Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940-3947.
44. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRllla gene. Blood. 2002;99:754-758.
45. Hatjiharissi E, Xu L, Santos DD, et al. Increased natural killer cell expression of CD16, and augmented binding and ADCC activity to rituximab among individuals expressing the FC7RIIIA-158 V/V and V/F polymorphism. Blood. 2007;110:2561-2564.
46. Yazawa N, Hamaguchi Y, Poe JG, Tedder TF. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. Proc Natl Acad Sci U SA. 2005;102:15178-15183.
47. Stockmeyer B, Schiller M, Repp R, et al. Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1 D10-a humanized human leukocyte antigen DR antibody. Br J Haematol. 2002:118:959-967.
48. Elasser D. Valerius T Repp R, et al. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating facto. Blood. 1996;87:3803-3812.
49. Bienvenu J, Chvetzoff R, Salles G, et al. Tumor necrosis factor a release is a major biological event associated with rituximab treatment. Hematol J. 2001;2:378-384.]
50. Nadler LM. Takvorian T, BotnickL et al. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet. 1984:2:427-431.